(MedPage Today) — The FDA has approved two targeted menin inhibitors for the treatment of relapsed/refractory NPM1-mutated acute myeloid leukemia (AML).
Ziftomenib (Komzifti) was approved on Thursday for adults with relapsed/refractory NPM1-mutated…
Source link : https://www.medpagetoday.com/hematologyoncology/leukemia/118506
Author :
Publish date : 2025-11-13 19:16:00
Copyright for syndicated content belongs to the linked Source.
